NCT06561386
Recruiting
Phase 3
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%
ConditionsNon-small Cell Lung Cancer
Overview
- Phase
- Phase 3
- Intervention
- Nivolumab
- Conditions
- Non-small Cell Lung Cancer
- Sponsor
- Bristol-Myers Squibb
- Enrollment
- 1000
- Locations
- 523
- Primary Endpoint
- Overall survival (OS) in randomized participants with PD-L1 1% to 49%
- Status
- Recruiting
- Last Updated
- last month
Overview
Brief Summary
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participants must have histologically confirmed Stage IV or recurrent Non-small Cell Lung Cancer (NSCLC) of non-squamous (NSQ) histology with no prior systemic anti-cancer therapy given as primary therapy for advanced or metastatic disease.
- •Participants must have measurable PD-L1 ≥ 1% Tumor Cell (TC) score by the investigational PD-L1 immunohistochemistry (IHC) assay VENTANA PD-L1 (SP263) CDx Assay conducted by central laboratory during the screening period prior to randomization.
- •Participants must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1 criteria.
- •Participants must have an Easter Cooperative Oncology Group (ECOG) performance status of ≤ 1 at screening.
- •Participants must have a life expectancy of at least 3 months at the time of randomization.
Exclusion Criteria
- •Participants must not be pregnant and/or breastfeeding.
- •Participants with epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS-1 mutations that are sensitive to available targeted inhibitor therapy. Participants with unknown EGFR, ALK, or ROS-1 status are excluded.
- •Participants with known BRAFV600E mutations, that are sensitive to available targeted inhibitor therapy; participants with known activating rearranged during transfection (RET) mutations or neurotrophic tyrosine receptor kinase (NTRK) fusion gene alterations are excluded. Participants with unknown or indeterminate BRAF mutation, activating RET mutations or NTRK fusion gene alterations are eligible.
- •Participants must not have untreated central nervous system (CNS) metastases.
- •Participants must not have leptomeningeal metastases (carcinomatous meningitis).
- •Participants must not have concurrent malignancy requiring treatment.
- •Participants must not have an active autoimmune disease.
- •Participants must not have history of interstitial lung disease or pneumonitis that required oral or intravenous (IV) glucocorticoids to assist with management.
- •Participants must not have a history of myocarditis.
- •Participants must not have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or other antibody or drug targeting T-cell co-stimulation or checkpoint pathways.
Arms & Interventions
Arm A
Intervention: Nivolumab
Arm A
Intervention: Relatlimab
Arm A
Intervention: Carboplatin
Arm A
Intervention: Pemetrexed
Arm A
Intervention: Cisplatin
Arm B
Intervention: Pembrolizumab
Arm B
Intervention: Carboplatin
Arm B
Intervention: Pemetrexed
Arm B
Intervention: Cisplatin
Outcomes
Primary Outcomes
Overall survival (OS) in randomized participants with PD-L1 1% to 49%
Time Frame: Up to 5 years
Secondary Outcomes
- OS in randomized participants with PD-L1 ≥ 1%(Up to 5 years)
- Progression-free survival (PFS) as assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR)(Up to 5 years)
- Overall response rate (ORR)(Up to 5 years)
- Duration of response (DoR)(Up to 5 years)
- Number of participants with adverse events (AEs)(Up to 2.5 years)
- Number of participants with serious adverse events (SAEs)(Up to 2.5 years)
- Number of participants with immune-mediated adverse events (IMAEs)(Up to 2.5 years)
- The time until definitive deterioration based on non-small cell lung cancer - symptom assessment questionnaire (NSCLC-SAQ) total score(Up to 2 years)
Study Sites (523)
Loading locations...
Similar Trials
Completed
Phase 3
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung CancerNCT02477826Bristol-Myers Squibb2,747
Completed
Phase 3
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)Unresectable or Metastatic MelanomaNCT01844505Bristol-Myers Squibb945
Active, not recruiting
Phase 3
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the CancerVarious Advanced CancerNCT02632409Bristol-Myers Squibb709
Terminated
Phase 3
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal CancerColorectal NeoplasmsNCT05328908Bristol-Myers Squibb770
Completed
Phase 3
A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma PatientsRecurrent GlioblastomaNCT02017717Bristol-Myers Squibb529